

REFERENCES

1. Calame K, Lin KI, and Tunyaplin C. Regulatory mechanism that determine the development and function of plasma cells. *Annu Rev Immunol.* 2003; 21: 205-30.
2. Kallies A and Nutt SL. Terminal differentiation of lymphocytes depends on Blimp-1. *Cur Opin Immunol* 2007; 19: 156-62.
3. Lin KI, Duclos CA, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cell to immunoglobulin M-secreting plasma cells. *Mol Cell Biol.* 2002; 22: 4771-80.
4. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. *Immunol cell Biol.* 2008; 86: 47-53.
5. Shelef SM, Lin KI, Williams Mc, Liao J, Williams MGM, and Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. *Immunity.* 2003; 19: 607-20.
6. Lin KI, Tunyaplin C, Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. *Immunol Rev.* 2003; 194: 19-28.

7. Martins G, Calame K. Regulation and Functions of Blimp-1 in T and B lymphocytes. *Annu Rev Immunol*. 2008; 26: 133-69
8. Tunyaplin C, Shapiro MA, Calame K. Characterization of the B lymphocyte-induced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter. *Nucleic Acids Res*. 2000; 28: 4846-55.
9. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. *Br J Haematol*. 2002; 116: 429-35.
10. Nilsson J, Söderberg O, Nilsson K, Rosén A. Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. *Immunol Lett*. 2004; 15: 83-9.
11. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. *Immunity*. 2004; 21: 81-93.
12. Nakase K, Ishimaru F, Fujii K, Tabayashi T, Kozuka T, Sezaki N, et al. Overexpression of novel short isoforms of Helios in a patient with T-cell acute lymphoblastic leukemia. *Exp Hematol*. 2002; 30: 313-7.

13. Tabayashi T, Ishimaru F, Takata M, Kataoka I, Nakase K, Kozuka T, et al.
Characterization of the short isoform of Helios overexpressed in patients with T-cell malignancies. *Cancer Sci.* 2007 Feb; 98(2):182-8.
14. Györy I, Fejér G, Ghosh N, Seto E and Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. *J Immunol*, 2003, 170: 3125-3133.
15. Keller AD and Maniatis T. Identification and characterization of a novel repression of beta-interferon gene expression. *Gene*. 1991; 5: 868-79.
16. Turner CA, Jr Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. *Cell*. 1994; 77: 297-306.
17. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. *J Exp Med*. 2004; 200: 967
18. Calame K. Transcriptional factors that regulate memory in humoral responses. *Immunol Rev*. 2006; 211: 269-79.

19. Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, McKenzie BS, et al.

Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. *Immunity*, 2007; 26: 555-566.

20. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. *Science*. 1997; 276: 596-9.

21. Sciammas R, Davis MM. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. *J Immunol*. 2004; 172: 5427-40.

22. Tooze RM, Stephenson S and Doody GM. Repression of IFN- γ Induction of Class II Transactivator: A Role for PRDM1/Blimp-1 in regulation of cytokine signaling. *J Immunol*, 2006, 177: 4584-4593.

23. Piskurich JF, Lin KI, Lin Y, Wang, Ting JPY, Calame K. BLIMP-1 mediates extinction of major histocompatibility class II transactivator expression in plasma cells. *Nat Immunol*. 2000; 1: 526-32.

24. Buckland J. B-cell Development: BLIMP-1, BCL-6 and B-cell fate. *Nat Rev Immunol*. 2002;2; 629

25. Johnson K, Shelef MS, Tunyaplin C, Calame K. Regulatory events in early and late B cell differentiation. *Mol Immunol*. 2005; 42: 749-61.

26. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald, A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*. 2002; 17: 51-62.
27. Marker KW and Wilson CB. Sound of a silent Blimp-1. *Nat Immunol*. 2004; 5: 241-2.
28. Northrup DL and Allman D. Transcriptional regulation of early B cell development. *Immunol Res*. 2008; 42: 106-17.
29. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. *Mol Cell Biol*. 2000; 20: 2592-603.
30. Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. *Nat Immunol*. 2004; 5: 299-308.
31. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. *Cancer Cell*. 2007; 11: 349-60.

31. Giorgio C, Cristina AD, Rita S, Zhou H, Wang D, Bachir A. PRDMI/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. *Pathology*. 2005; 206: 76-86.

32. Schmidt D, Nayak A, Schumann JE, Schimpl A, Berberich I, Berberich-Siebelt F. Blimp-1 Δ 7: A naturally occurring Blimp-1 deletion mutant with auto-regulatory potential. *Exp Cell Res*. 2008; 314: 3614-3627.

33. Petsophonsakul W, Kaewrakmuk, J, Punyot, M, Charoenkwan P and Nawarawong. Expression of Blimp-1 transcription factors mRNA isoforms in mononuclear cells from bone marrow of leukemia and lymphoma patients. The 13th International congress of immunology, Rio de Janeiro-Brazil, August 21-25, 2007.

34. Shapiro-Shelef M, Lin-I K, Savitsky D, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. *J Exp Med* 2005; 202(11): 1471-76. http://www.nature.com/ni/journal/v1/n6/full/ni1200_526.html - a2#a2

APPENDIX

Reagents and buffers

Carbonate buffer (coating buffer)

Na_2CO_3	1.6	g
NaHCO_3	2.9	g
NaN_3	0.2	g

Dissolve reagents in 500 ml distilled water and adjust pH to 9.5 with 1N HCl or 1N NaOH, and then fill distilled water up to 1,000 ml. Store at 4°C.

Phosphate buffer saline

NaH_2PO_4 (anhydrous)	0.23	g
Na_2HPO_4 (anhydrous)	1.15	g
NaCl	9.00	g

Dissolve reagents in 500 ml distilled water and adjust pH to 7.2-7.4 with 1N HCl or 1N NaOH, and then fill distilled water up to 1,000 ml. Store at 4°C.

PBS-Tween

Phosphate buffer saline	1,000	ml
Tween 20	500	μl

Mix well and store at 4°C.

5% BSA

Phosphate buffer saline	100	ml
BSA	5	g

Mix well and store at 4°C.

10x TBE buffer

Tris Base	108	g
Boric acid	55	g
0.5 M EDTA pH 8.0	40	ml

Dissolved reagents in 500 ml distilled water and then fill distilled water up to 1,000 ml

Store at room temperature.

6x loading buffer

Formamide	2700	μl
10x TBE	150	μl
Xylene cyanol	0.6	mg
Bromophenol blue	0.6	mg
Distilled water	150	μl


Store at 4°C.

RPMI-10

RPMI medium	500	ml
FBS	50	ml
Sodium pyruvate 100X	5	ml
Gentamycin (40 mg/ml)	625	μl


Sterile filtration using 0.45 μm Millipore filter and check sterility by incubation of 2 ml medium in 5% CO₂ at 37°C for a week. Medium was stored at 4°C.

Titration of FITC-conjugated Antibody
Antibody 1:100



	Unstained	Conjugated control	Blimp-1
% Cell	21.5	50.1	92.7
FITC Mean	251	301	376
FITC Median	131	229	322

Antibody 1:200






	Unstained	Conjugated control	Blimp-1
% Cell	21.5	47.5	90.1
FITC Mean	251	301	376
FITC Median	131	229	322

Comparison of permeabilizing agent Cold Methanol

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	9.2	41.1	82.4
FITC Mean	251	301	376
FITC Median	131	229	322

Triton x 100

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	18.9	39.0	80.8
FITC Mean	178	188	246
FITC Median	131	140	215

Unstimulated Raji cell CD138 day 0

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	39.7	41.0	51.7
FITC Mean	210	225	347
FITC Median	158	166	190

Unstimulated Raji cell CD138 day 3

Unstained

Conjugated control


CD 138



	Unstained	Conjugated control	CD 138
% Cell	42.2	43.4	57.6
FITC Mean	193	193	245
FITC Median	166	164	188

Unstimulated Raji cell CD138 day 6


Unstained Conjugated control CD 138



	Unstained	Conjugated control	CD 138
% Cell	38.2	41.5	56.4
FITC Mean	203	202	289
FITC Median	170	169	255

Unstimulated Raji cell CD138 day 9

Unstained Conjugated control CD 138






	Unstained	Conjugated control	CD 138
% Cell	44.9	46.3	52.5
FITC Mean	204	215	294
FITC Median	164	176	251

Stimulated Raji cell CD138 day 3

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	41.8	42.4	52.4
FITC Mean	192	189	132
FITC Median	164	160	190

Stimulated Raji cell CD138 day 6

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	40.3	40.4	54.7
FITC Mean	195	200	263
FITC Median	166	172	219

Stimulated Raji cell CD138 day 9

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	46.1	50.0	60.4
FITC Mean	202	204	305
FITC Median	169	172	260

Unstimulated Raji cell Blimp-1 day 0

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	28.2	30.4	40.6
FITC Mean	253	2015	1437
FITC Median	198	233	223

Unstimulated Raji cell Blimp-1 day 3

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	26.3	31.5	32.2
FITC Mean	269	915	631
FITC Median	202	221	198

Unstimulated Raji cell Blimp-1 day 6

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	24.4	29.1	32.7
FITC Mean	254	285	271
FITC Median	198	211	213

Unstimulated Raji cell Blimp-1 day 9

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	22.6	27.2	37.8
FITC Mean	272	302	245
FITC Median	206	216	197

Stimulated Raji cell Blimp-1 day 3

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	24.2	32.5	28.5
FITC Mean	313	400	522
FITC Median	200	213	209

Stimulated Raji cell Blimp-1 day 6

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	Blimp-1
% Cell	25.2	25.1	27.8
FITC Mean	255	254	256
FITC Median	198	209	206

Stimulated Raji cell Blimp-1 day 9

Unstained

Conjugated control


Blimp-1




	Unstained	Conjugated control	Blimp-1
% Cell	24.9	27.8	54.3
FITC Mean	246	316	228
FITC Median	207	209	189

LP-1 cell CD138 day 0


Unstained



Conjugated control




CD 138




	Unstained	Conjugated control	CD 138
% Cell	45.9	50.6	83.6
FITC Mean	202	207	511
FITC Median	163	166	284

LP-1 cell CD138 day 3


Unstained



Conjugated control



CD 138






	Unstained	Conjugated control	CD 138
% Cell	31.4	25.3	74.4
FITC Mean	215	185	588
FITC Median	161	143	303

LP-1 cell CD138 day 6

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	25.7	36.8	81.4
FITC Mean	155	184	449
FITC Median	128	158	289

LP-1 cell CD138 day 9

Unstained

Conjugated control

CD 138






	Unstained	Conjugated control	CD 138
% Cell	46.4	51.2	86.1
FITC Mean	186	200	595
FITC Median	159	162	382

LP-1 cell BLIMP-1 day 0

Unstained

Conjugated control

Blimp-1






	Unstained	Conjugated control	CD 138
% Cell	48.5	53.8	57.8
FITC Mean	199	658	666
FITC Median	153	161	166

LP-1 cell BLIMP-1 day 3

Unstained

Conjugated control


Blimp-1




	Unstained	Conjugated control	Blimp-1
% Cell	44.1	48.6	56.5
FITC Mean	205	659	458
FITC Median	145	158	161

LP-1 cell BLIMP-1 day 6


Unstained



Conjugated control




Blimp-1




	Unstained	Conjugated control	Blimp-1
% Cell	32.5	33.8	50.4
FITC Mean	177	178	243
FITC Median	140	142	143

LP-1 cell BLIMP-1 day 9


Unstained



Conjugated control



Blimp-1



	Unstained	Conjugated control	Blimp-1
% Cell	41.1	51.7	70.5
FITC Mean	179	187	241
FITC Median	142	153	178



CURRICULUM VITAE

Name Mr. Jedsada Kaewrakmuk

Date of Birth March 5, 1982

Education 2006: Bachelor of Science (Medical Technology),
Faculty of Associated Medical Science, Chiang Mai University,
Chiang Mai, Thailand

